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with ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C genotype 2/3 in 
Brazilian Public Health System (SUS). METHODS: To project disease progression, a 
Markov model was built based on clinical stages of chronic disease. A Delphi panel 
was conducted to evaluate direct medical resources related to each stage, followed by 
micro-costing of the results. Perspective was from a public payer. Source used for 
costing was government reimbursement procedures list (SAI/SIH–SUS). Drug acquisi-
tion costs for a 70 kg patient were obtained from ‘Banco de Preços em Saúde’, govern-
ment ofﬁcial source. Costs were reported in 2009 Brazilian Reais (US$1≈$Brz1.7). 
Efﬁcacy of pegylated-interferons was obtained from a meta-analysis of 7 RTCs com-
paring the drugs, detailed elsewhere. For genotype 2/3, median rate of sustained 
virological response was 79.2% for peginterferon-alfa-2a and 73.8% for peginter-
feron-alfa-2b. Discount rate for costs and outcomes was 5%, according to Brazilian 
guidelines for HTA. RESULTS: Assuming a lifetime perspective, expected costs and 
outcomes for peginterferon-alfa-2a were $Brz15,898, 15.21LYs and 14.57QALYs; for 
peginterferon-alfa-2b, $Brz18,439, 15.11LYs and 14.32QALYs. Cost-effectiveness 
analysis estimated an ICER of -$Brz25,289/LY and -$Brz10,426/QALYs for peginter-
feron-alfa-2a, being the dominant therapy. For each 1000 patients treated with 
peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted can be up to 
$Brz2,5 million which would allow treatment of 160 more patients. CONCLUSIONS: 
These ﬁndings suggest that treatment with peginterferon-alfa-2a is more effective and 
less costly when compared to peginterferon-alfa-2b under SUS perspective in Brazil.
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Chronic hepatitis C affects approximately 180 million people worldwide being one of 
the main causes of chronic liver disease. About 20% of patients with chronic hepatitis 
C can develop cirrhosis over 20 years, thus presenting risk of developing hepatic 
complications. Treatment is currently based on pegylated-interferon-alfa-2a or alfa-2b 
plus ribavirin. Sustained virologic response (SVR) is associated with a better prognosis 
compared to untreated patients and treatment failures. OBJECTIVES: To compare 
treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, 
both plus ribavirin, in the therapeutic scheme of 48 weeks for hepatitis C genotype 1 
in Brazilian Public Health System (SUS). METHODS: To project disease progression, 
a Markov model was built based on clinical stages of chronic disease. A Delphi panel 
was conducted to evaluate direct medical resources related to each stage, followed by 
micro-costing of results. Perspective was from a public payer. Costing was based on 
government reimbursement procedures list (SAI/SIH–SUS). Drug acquisition costs 
(70 kg patient) were obtained from ‘Banco de Preços em Saúde’, government source. 
Costs were in 2009 Brazilian Reais (US$1≈$Brz1.7). Efﬁcacy of pegylated-interferons 
was obtained from a meta-analysis of 7 RTCs comparing the drugs, detailed else-
where. For genotype 1, SVR median rate was 42.1% for peginterferon-alfa-2a and 
33.3% for peginterferon-alfa-2b. Discount rate (costs and outcomes) was 5%, accord-
ing to Brazilian guidelines for HTA. RESULTS: Assuming a lifetime perspective, 
expected costs and outcomes for peginterferon-alfa-2a were $Brz36,713, 14.51LYs 
and 12.89QALYs; for peginterferon-alfa-2b $Brz41,191, 14.35LYs and 12.49QALYs 
gained. Cost-effectiveness analysis estimated an ICER of -$Brz27,266/LY and 
-$Brz11,277/QALY for peginterferon-alfa-2a, being the dominant therapy. For each 
1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, 
savings granted can be up to $Brz4,4 million which would allow treatment of 120 
more patients. CONCLUSIONS: Findings suggest that treatment with peginterferon-
alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under 
SUS perspective in Brazil.
PGI19
COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH 
PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR 
PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE 
PRIVATE PAYER PERSPECTIVE IN BRAZIL
Barros FMR1, Cheinquer H2, Borges LG3, Santos E3
1Hospital Português de Beneﬁcência em Pernambuco and Hospital das Clínicas - UFPE, 
Recife, Brazil, 2Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto 
Alegre, Brazil, 3Roche Brazil, São Paulo, Brazil
Hepatitis C affects approximately 180 million people worldwide and is currently one 
of the main causes of chronic liver disease. HCV infection progresses to chronicity in 
up to 80% of infected individuals, from whom approximately 20% progress to cir-
rhosis over 20 years. These individuals are at risk of developing hepatic failure and/
or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs and out-
comes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated with 
ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C in Brazilian private 
market for the treatment of HCV infection genotypes 2/3. METHODS: To project 
disease progression, a Markov model was built based on clinical stages of chronic 
disease. A Delphi panel was conducted to evaluate direct medical resources related to 
each stage, followed by micro-costing of the results. The perspective was from a private 
payer. Source used for costing was medical society physicians fee list (CBHPM-2008). 
Drug acquisition costs for a 70kg patient were obtained from ofﬁcial public sources 
(Kairos Magazine-Nov2009). Costs were reported in 2009 Brazilian Reais 
(US$1≈$Brz1.7). Efﬁcacy of pegylated-interferons was obtained from a meta-analysis 
of 7 RCTs comparing the drugs, detailed elsewhere. For genotype 2/3, median rate of 
sustained virological response was 79.2% for peginterferon-alfa-2a and 73.8% for 
peginterferon-alfa-2b. Discount rate for costs and outcomes was 5%, according to 
Brazilian guidelines for HTA. RESULTS: Assuming a lifetime perspective, expected 
costs and outcomes for peginterferon-alfa-2a were $Brz48,363, 15.21LYs and 
14.57QALYs; for peginterferon-alfa-2b, $Brz52,154, 15.11 LYs and 14.32QALYs. 
Cost-effectiveness analysis estimated an ICER of -$Brz37,614/LY and -$Brz15,556/
QALYs for peginterferon-alfa-2a, being the dominant therapy. For each 1000 patients 
treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted 
can be up to $Brz3,8 million which would allow treatment of 78 more patients. 
CONCLUSIONS: These ﬁndings suggest that treatment with peginterferon-alfa-2a is 
more effective and less costly when compared to peginterferon-alfa-2b under private 
payer perspective in Brazil.
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OBJECTIVES: Whether the use of alvimopan is cost-effective, compared to the stand-
ard post-operative care, for post-operative ileus (POI) among patients undergoing 
small- or large-bowel resection via laparotomy. METHODS: We constructed a formal 
decision model from the health care system perspective. The clinical outcomes (time 
to discharge order written [DCO], post-operative nasogastric tube insertion, POI-
related readmission within 7 days, nausea and vomiting) were obtained from meta-
analyses of published studies. Cost inputs included costs associated with the drugs, 
nursing labor, readmission, and hospitalization. Cost-consequence was assessed by 
determining the net cost of alvimopan use and subsequent reduction in length of stay 
(LOS). Sensitivity analyses were conducted. RESULTS: The alvimopan drug cost was 
$570 based on an average of 9.5 doses. Given the 18.4-hour mean reduction in DCO, 
the use of alvimopan reduced hospitalization costs by $2021. In the base-case, alvi-
mopan resulted in a $1187 per-person cost savings. In sensitivity analyses, the result 
was robust to changes in key parameters including the cost and number of doses of 
alvimopan, DCO, readmission rates, and hospitalization cost. In scenario analyses, 
alvimopan use yielded a cost saving of $897 when no difference in readmission rates 
was assumed. However, when no difference in DCO was asssumed, the total cost of 
care with alvimopan was $278 greater. Similarly, it was $569 greater when both 
readmission rates and DCO were assumed to be equal between strategies. In Monte 
Carlo simulation, the mean difference in overall cost of care was $1252 (95% certainty 
interval: -$398 to $6306), favoring the use of alvimopan. CONCLUSIONS: The 
overall hospitalization cost reduction associated with the use of alvimopan offsets the 
drug cost. Alvimopan appears to be cost-saving for POI among patients undergoing 
bowel resection via laparotomy. This ﬁnding is not applicable to the less-invasive 
laparoscopic surgical approach which has been associated with decreased post-oper-
ative morbidity and LOS.
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OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of entecavir 
and telbivudine in HBeAg-positive/-negative chronic hepatitis B (CHB) patients based 
on the ability of each drug to suppress viral replication. METHODS: A cost-effective-
ness analysis was performed to evaluate the impact of treatment on disease morbidity 
and costs over the lifetime and the short term (10 years) for a patient based on a 
societal perspective. A decision tree was developed to assess the drug abilities to sup-
press HBV DNA replication. To obtain probability estimates with HBV DNA levels 
and resistance rates of entecavir and telbivudine, recent entecavir-lamivudine BEHoLD 
studies and telbivudine-lamivudine GLOBE studies were indirectly compared. The 
risks of progression to compensated cirrhosis (CC), decompensated cirrhosis (DC), or 
HCC were derived from the REVEAL-HBV study, which was to evaluate the relation-
ship between hepatitis B viremia and progression to cirrhosis and HCC. For the life 
expectancy of DC and HCC, the declining exponential approximation of life (DEALE) 
method was applied based on the published annual mortality rates of DC and HCC. 
Both direct and indirect medical costs were included and univariate sensitivity analyses 
were performed on parameters in the model to evaluate the impact of parameter 
uncertainty. RESULTS: On a per-person basis, the ICERs of entecavir compared to 
telbivudine for lifetime therapy were $13,649 and $52,776 in HBeAg-positive and 
HBeAg-negative CHB, respectively. In the 10-year model, the ICERs were $US 39,089 
and $US 365,100 in HBeAg-positive and HBeAg-negative CHB, respectively. One-way 
sensitivity analyses showed that the model was robust to most parameters. However, 
parameters such as drug costs, discount rate and average time to events from study 
entry were sensitive. CONCLUSIONS: For lifetime therapy and for HBeAg-positive 
patients, entecavir was cost effective compared to telbivudine. However, in the short-
term treatment model for HBeAg-negative CHB, entecavir was not cost-effective.
